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Advanced ovarian carcinoma in early progression (o6 months) (AOCEP) is considered resistant to most cytotoxic drugs.
Gemcitabine (GE) and oxaliplatin (OXA) have shown single-agent activity in relapsed ovarian cancer. Their combination was tested
in patients with AOCEP in phase II study. Fifty patients pre-treated with platinum–taxane received q3w administration of OXA
(100mgm
–2, d1) and GE (1000mgm
–2, d1, d8, 100-min infusion). Patient characteristics were a : median age 64 years (range
46–79),and 1 (84%) or 2 (16%) earlier lines of treatment. Haematological toxicity included grade 3–4 neutropaenia (33%), anaemia
(8%), and thrombocytopaenia (19%). Febrile neutropaenia occurred in 3%. Non-haematological toxicity included grade 2–3 nausea
or vomiting (34%), grade 3 fatigue (25%),and grade 2 alopecia (24%). Eighteen (37%) patients experienced response. Median
progression-free (PF) and overall survivals (OS) were 4.6 and 11.4 months, respectively. The OXA–GE combination has high activity
and acceptable toxicity in AOCEP patients. A comparison of the doublet OXA–GE with single-agent treatment is warranted.
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With platinum taxane-based chemotherapy and debulking surgery,
70–80% of patients with advanced ovarian cancer are free of
clinical disease (Kerbrat et al, 2001). Although primary chemo-
therapy achieves high response rates, about 75% of patients will
subsequently relapse with incurable disease (Lhomme et al, 2004).
Relapsed patients can be classified into one of three categories,
according to the therapy-free interval (TFI) between the end of
platinum-based chemotherapy and relapse. Those with TFI 46
months generally have relatively chemo-sensitive tumours that
may respond to platinum therapy (platinum-sensitive disease)
(Markman and Hoskins, 1992). In contrast, patients with TFI o6
months or no response to initial therapy (chemo-resistant
or -refractory disease) have an extremely poor outcome
(Eisenhauer et al, 1997). The prognosis of patients who progress
during first-line chemotherapy or who experience an early relapse
(treatment-free interval o6 months) is extremely poor, with o5%
long-term disease-free survival (Eisenhauer et al, 1997; Gordon
et al, 2001). In these cases, standard treatment consists of single-
agent regimens for palliation and disease control.
Oxaliplatin (OXA) is a diaminocyclohexane platinum derivative
non-cross resistant to cisplatin. Oxaliplatin–DNA adducts are not
recognised by the proteins of the mismatch repair system (Fink
et al, 1997). This may explain the activity of OXA in platinum-
resistant ovarian cancers (Fink et al, 1996; Raymond et al, 2002).
In a randomised study of 86 relapsed ovarian cancer patients, OXA
at a dose of 130mgm
–2 q3w has yielded median response rates
and time to progression similar to those of paclitaxel (Piccart et al,
2000). Gemcitabine (GE) is an antimetabolite that inhibits DNA
synthesis and blocks DNA repair pathways, a modulation that may
be useful in overcoming platinum resistance.
The combination of OXA and GE is synergistic in vitro
(Raymond et al, 2002). We hypothesised that this combination
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smight provide more effective therapy for patients with relapsed
ovarian cancer. The present multicentre phase II trial was
designed to evaluate the efficacy and toxicity profile of OXA
100mgm
–2, d1, combined with GE 1000mgm
–2,d 1a n dd 8 ,
every 3 weeks in patience with advanced ovarian carcinoma in
early progression (AOCEP).
PATIENTS AND METHODS
Objectives
The primary objective of the present study was to assess the anti-
tumour activity of the OXA–GE combination in AOCEP patients.
The main criterion for efficacy was objective response rate;
secondary criteria were time to progression, response duration,
and overall survival (OS). Our secondary objective was to
determine the type, severity, and frequency of adverse events
associated with OXA–GE treatment in these patients. The study
design was an open, non-comparative, prospective phase II study.
The study was carried out according to good clinical practice
guidelines, in accordance with the declaration of Helsinki, and was
approved by local ethics committees. Approval was gained from
local review boards, and written informed consent was obtained
from each participant before inclusion. An independent monitor-
ing institute was responsible for data control.
Patients’ eligibility
Eligibility criteria were: age 418 years; histologically confirmed
diagnosis of advanced ovarian cancer; recurrent ovarian cancer
treated with one or two earlier lines of platinum- and taxane-based
chemotherapy, the last one consisting of a carboplatin–paclitaxel
combination; measurable or evaluable disease documented by
imaging according to the response evaluation criteria for solid
tumours (RECIST), and blood CA 125 level 440UI; progression of
disease during first-line treatment, or treatment-free interval
before inclusion o6 months; Eastern Cooperative Oncology Group
(ECOG) performance status score o2; adequate haematological
and organ functions; and written informed consent.
Exclusion criteria were: previous treatment with 42 lines of
chemotherapy, previous total abdominal radiotherapy; brain or
meningeal metastasis; grade 41 peripheral neuropathy according
to the National Cancer Institute—Common Toxicity Criteria
(NCI—CTC) version 2.0; severe cardiac dysfunction or uncon-
trolled hypertension; previous or concurrent malignancy other
than ovarian cancer (with the exception of cutaneous basal cell
carcinoma and cervical intraepithelial neoplasia); concurrent
serious, uncontrolled medical (including bowel occlusion or
subocclusion) or psychiatric disease; previous treatment with either
OXA or GE; glomerular filtration rate calculated according to the
Cockroft–Gault formula o60mlmin
–1, total bilirubin concentra-
tion 41.25 upper normal limit, liver transaminases 42.5 upper
normal limit, absolute neutrophil count o2.0 10
9 l
–l, and platelet
count o100 10
9l
–l.
Treatment plan and drug administration
In all eligible patients treatment was administered through a
central venous catheter: GE 1000mgm
–2 on days 1 and 8,
administered over 100min (10mgm
–2min
–1) after dilution in
250ml normal saline, and OXA 100mgm
–2on day 1, administered
over 2h 30min after GE infusion after dilution in 250ml of 5%
glucose. All patients received standard antiemetic prophylaxis.
Treatment was repeated every 21 days if blood counts returned to
normal levels (neutrophil 41.5 10
9 l
–land platelets 4100 10
9 l
–l)
and non haematological toxicity resolved to grade o1.
This regimen was given for a minimum of two cycles in the
absence of disease progression, unacceptable toxicity or patient
refusal. An evaluation of response was performed after two courses
to determine whether the treatment should be continued, then
repeated every two cycles. After six courses, the patients could
continue therapy for three further cycles if, in the opinion of the
attending physician, further clinical benefit could be expected.
Dose modifications
Treatment delays or dose modifications were decided based on
NCI—CTC toxicity grading performed on each treatment day.
Haematological toxicity Patients with neutropenic fever, grade 4
neutropaenia lasting 47 days or grade 4 thrombocytopaenia could
continue treatment with a reduction of one dose level for each drug
(OXA 85mgm
–2on day 1 and GE 800mgm
–2day
–1on days 1 and
8). The use of granulocyte-colony stimulating factor (G-CSF) was
then authorised, at the physician’s discretion.
In case of recovery to an absolute neutrophil count of
X1.5 10
9 l
–l or more and a platelet count 4100 10
9 l
–lin
p 7 days, OXA and GE doses were reduced by one dose level. Any
delay of 414 days in any course of treatment necessitated patient
withdrawal from the study.
Day 8 of GE administration was suppressed if blood counts on
that day showed an absolute neutrophil count of o0.5 10
9 l
–l
and a platelet count of o50 10
9 l
–l. Day 8 dose of GE was
reduced to 600mgm
–2 if blood counts on that day showed an
absolute neutrophil count between 0.5 10
9 l
–l and 1.5 10
9 l
–l,
and or a platelet count between 50 10
9 l
–l and 100 10
9 l
–l.
Non-haematological toxicity Oxaliplatin was reduced to
85mgm
–2 in case of grade 1 peripheral neurotoxicity, to
65mgm
-2 in case of grade 2, and stopped in case of grade 3.
It was discontinued in patients with grade 3 hypersensitivity
reaction. Gemcitabine was reduced to 800mgm
–2in case of grade
42 mucositis.
Patients who required more than two dose reductions of the
same drug were withdrawn from the study treatment. When dose
reduction was required, no subsequent dose escalation was
allowed.
Evaluation of response and survival
Procedures for disease evaluation included standard physical
examination and CA 125 level determination at each cycle, as well
as computed tomography scan of the abdomen and pelvis and two-
view chest X-ray every two courses. Objective responses were
evaluated using the RECIST (Therasse et al, 2000). In the absence
of measurable disease, serologic response was determined accord-
ing to CA 125 level kinetics using GCIG criteria (Vergote et al,
2000).
Duration of response was measured from the time of initial
documented response to the first sign of disease progression.
Overall survival was evaluated by measuring the interval from the
beginning of treatment to the date of last follow-up or date of
death, whichever occurred first. Time to progression was defined
as the time from the date of treatment to documentation of tumour
progression.
Determination of toxicity
Toxicity was evaluated using the NCI—CTC scale, version 2.0. All
documented side effects were included, regardless of their
relationship to study treatment. Haematological toxicity was
evaluated weekly by complete blood count, whereas non-haema-
tological toxicity was assessed before each treatment cycle.
Chemotherapy was administered when the patient’s neutrophil
count was 41.5 10
9 l
–l, and the platelet count 4100 10
9 l
–l.
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sCriteria for withdrawal from the study
Patients were removed from the study for any of the following
reasons: (i) evidence of progressive disease after a minimum of two
cycles of therapy; (ii) development of unacceptable toxicity; (iii)
patient’s refusal or inability to comply with protocol requirements.
Statistical analysis
A multi-stage phase II Fleming design was used to test whether the
efficacy rate (response rate) was at least 20%, which we viewed as
clinically promising, or at most 5%, which we viewed as not
clinically promising (Fleming, 1982). With 45 evaluable patients,
this trial had 90% power to detect an efficacy of 20% with a 0.05
level of significance. Interim analysis was performed after the first
15 and 30 patients. As we expected a 10% rate of ineligibility, the
total number of patients planned for inclusion in the study was 50.
The primary end-point of our study was objective response (CR
plus PR). The response rate was calculated from all included
patients based on the intention-to-treat principle, with determina-
tion of the corresponding 95% confidence interval (CI). Survival
rates and time to progression were analysed by the Kaplan–Meier
method using SPSSs version 10.0.
RESULTS
Patient characteristics
From May 2001 to May 2002, 50 patients were enrolled into the
study. Patient characteristics are described in detail in Table 1. The
median age was 64 years (range 46–79). All patients received a
platinum–taxane regimen as first-line treatment. A majority of
them had received only one earlier line of chemotherapy. Of the
eight patients treated in the third line, five had received earlier
treatment with carboplatin alone, one with topotecan, one with
carboplatin followed by anti-aromatases, and one with a combina-
tion of anthracyclins, paclitaxel and carboplatin. Overall, half of
the patients had measurable disease, whereas 46% had no
measurable disease but elevated levels of CA 125.
One patient, who did not receive any study treatment owing to
rapid clinical deterioration due to bowel obstruction, was excluded
from all statistical evaluations.
Treatment
A median of six cycles (range, 1–9) was administered. Twenty-six
(52%) of the 50 patients received the planned six cycles. The major
cause for early discontinuation was disease progression in 17
patients, whereas seven patients did not complete the study
because of adverse events (three patients), death without disease
progression (two patients: one pulmonary embolism, one myo-
cardial infarction), patient or physician decision (two patients).
The median dose of GE on day 1 remained close to 1000mgm
–2
for all 211 cycles administered. Of the 422 doses of GE planned, 37
(8.8%) were omitted (D8) and 57 (13.5%) were reduced, mainly
because of neutropaenia, with a relative mean dose intensity of
85%. Of the 211 doses of OXA, none (0%) was omitted and 19 (9%)
were reduced, mainly because of neurotoxicity. The median dose
of OXA gradually decreased from 100mgm
–2 at cycle one to
96.8mgm
–2 at cycle six, with a relative mean dose intensity of
93%.
Clinical response
The overall response rate at the end of treatment (six cycles) was
37% (95% CI, 24–52%) (Table 2). With a median follow-up of 16
months, the median progression-free survival (PFS) for the whole
group was 4.6 months (range 0.3–10.4), and the median OS was
11.4 months (range 0.9–27) (Figure 1). The objective response rate
in patients with measurable disease was 31% (n¼26). In patients
with only CA 125 assessable disease (n¼23), the response rate
evaluated according to CA 125 GCIG criteria was 43%. Interest-
ingly, no PFS differences were seen according to the method of
response evaluation: patients with partial or complete response
evaluated with the clinical RECIST criteria had a PFS of 6.8 months
vs 6.5 months for those who were evaluated with GCIG serological
criteria. Patients with stable disease had a PFS of 4.9 and 4.2
Table 1 Patient characteristics (n¼50)
Characteristics % n
Age (years)
Median 64
Range 46–79
Histological type
Serous 78 39
Endometrioid 4 2
Others 18 9
Histological grade
11 6 8
22 8 1 4
32 6 1 3
Unknown 30 15
Number of earlier chemotherapy regimens
One 84 42
Two 16 8
Response to earlier platinum–taxane regimen
Clinical complete 42 21
Clinical partial 26 13
Stabilisation 16 8
Progression 10 5
Unknown 6 3
Performance status
03 2 1 6
16 8 3 4
Ascites 48 24
Measurable lesion
o5cm 40 20
X5cm 10 5
No (CA 125 X40UIml
–1)4 6 2 3
Not evaluable 4 2
Number of disease sites
a
15 5 2 7
414 5 2 3
aPeritoneal or retroperitoneal or single visceral disease.
Table 2 Response rates
Response
evaluation
Measurable
disease
no. (%)
CA 125
assessable
no. (%)
Total
no. (%)
Overall response 8 (31) 10 (43) 18 (37)
Stable disease 8 (31) 5 (22) 13 (27)
Progression 10(38) 6 (26) 16 (33)
Not evaluable — 2 (9) 2 (3)
Total 26 (100) 23 (100) 49 (100)
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smonths according to clinical and serological evaluation, respec-
tively. Finally, progressive patients had a very poor median PFS of
1.4 months.
Although the trial was not designed to evaluate treatment
activity in the different subsets of patients, we analysed response
rates according to the treatment-free interval. For the five patients
who had undergone progression under prevoius chemotherapy, no
response to the GE–OXA combination was observed. The response
rate was 44% (4/9 patients) for patients who relapsed between 0
and 3 months after previous therapy, and 42% (14/33 patients) for
those who relapsed in the 3–6-month interval.
Toxicity
A total of 211 chemotherapy cycles were administered to the 50
enrolled patients (median 6; range 1–8). Haematological side
effects represented the main toxicity of the GE–OXA combination
(Table 3). Blood transfusions were required in seven patients
(12%) and platelet transfusions in two. Nine patients (18%) were
treated with epoetin. Granulocyte-colony stimulating factor
administration, which was given only in case of G4 neutropaenia
accompanied with fever or persisting 47 days, was necessary for
eight patients (16%), and two of them were hospitalised.
The main non-haematological toxicities are summarised in
Table 4. No grade 4 non-haematological toxicity was observed.
Neuropathy occurred in 14 patients, but in only four of them (7%)
symptoms were severe enough to compromise the activities of
daily living and only one patient required discontinuation of
treatment. Alopecia was not evaluated as most of the patients
presented with pre-existing alopecia at enrolment because of
earlier treatments. There were no unexpected non-haematological
toxicities.
DISCUSSION
The identification of new drug combinations is a major challenge
to improve the anti-tumour activity and toxicity profile of
chemotherapy in patients with advanced tumours. This phase II
study shows that the combination of GE and OXA is active in
earlier treated patients with advanced ovarian cancer refractory to
platinum–taxane administration, and achieves an overall response
rate of 37% (95% CI, 24–52%). These results are encouraging
when compared with other chemotherapeutic agents, that is,
liposomal pegylated doxorubicin or topotecan and weekly
paclitaxel, or GE used alone, which achieve objective overall
response rates of only 10–20% in clinical trials conducted in the
same setting (Gordon et al, 2001; Markman et al, 2006; Ferrandina
et al, 2008).
The regimen used in the present trial is derived from the phase I
study conducted by Mavroudis et al in patients with advanced
solid tumours with increasing doses of GE 1000–1600mgm
–2 on
days 1 and 8, combined with OXA 60–120mgm
–2 on day 8,
repeated every 21 days. The dose-limiting toxicities were grade
3–4 neutropaenia, thrombocytopaenia and asthaenia (Mavroudis
et al, 2000). The doses of GE and OXA used in our study were 25%
lower than those recommended in the phase I study by Mavroudis
et al to account for the increased toxicity of chemotherapy in the
subset of refractory or resistant ovarian cancer patients. The
regimen was remarkably well tolerated by our patients regarding
haematological, digestive, and renal toxicities, the major toxic
reactions being neutropaenia and peripheral neuropathy. The once
every 3 weeks schedule of administration allowed to maintain
treatment dose intensity, with 93% of planned cycles effectively
administered at the planned dose. The main cause of treatment
delay was haematological toxicity. Cumulative non-haematological
toxicities were asthaenia and paraesthesia, as earlier reported with
GE and OXA, respectively (Mavroudis et al, 2000; Faivre et al,
2002). No bleeding and rare sepsis episodes (3%) were observed,
and only two patients required platelet transfusion. Digestive
toxicity was easily manageable with classical anti-emetics. As OXA
has no renal toxicity, treatment could be given on an out-patient
basis.
Other schedules of the GE–OXA combination have been tested
in phase I (Mavroudis et al, 2000; Gandara et al, 2001; Faivre et al,
2002) and phase II trials in different diseases and lines of treatment
(Table 5). Two main schedules have been reported: concurrent
administration of GE and OXA once every 2 weeks or once every
3 weeks (with GE given at days 1 and 8). If grade 3–4
Months
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Figure 1 Progression–free survival (PFS) (light grey line) and overall
survival (OS) (red line) for the all population (n¼50). A full colour version
of this figure is available at the British Journal of Cancer online.
Table 3 Worst haematological toxicities, and treatments
NCI—CTC grade 3–4
% Cycles % Patients
Leucopaenia 20 27
Neutropaenia 33 51
Thrombocytopaenia 19 26
Anaemia 8 12
Febrile neutropaenia 3 3
G-CSF use 14 16
EPO use 15 18
RBC transfusion 6 12
Platelet transfusion 6 3
Abbreviations: EPO¼erythropoietin; G-CSF¼granulocyte-colony stimulating factor;
NCI—CTC¼National Cancer Institute—Common Toxicity Criteria; RBC¼red
blood cells.
Table 4 Non-haematological toxicities
NCI—CTC grade (% patients)
Toxicity 1 2 3 4
Nausea or vomiting 28 25 7 —
Mucositis 10 8 4 —
Constipation 11 12 — —
Diarrhoea 9 3 — —
Infection 5 11 2 —
Neuropathy 21 6 1 —
Asthaenia 26 33 8
Hypersensitivity 0 0 2
Abbreviation: NCI—CTC¼National Cancer Institute—Common Toxicity Criteria.
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shaematological toxicity seems slightly more frequent with the
3-weekly regimen (440% vs o20%), grade 2–3 peripheral neuro-
pathy is clearly more frequent with the every 2-week schedule
(420% vs o10%), giving the opportunity to the physician and the
patient to choose the more appropriate schedule as a function of
earlier toxicity and late adverse effects of earlier treatments.
The combination of GE and OXA has been reported to show
activity in ovarian cancer both in earlier treated (Faivre et al, 2002;
Raspagliesi et al, 2004; Germano et al, 2007; Harnett et al, 2007)
and in first-line treated (Steer et al, 2006) patients. Platinum-
resistant or platinum-refractory patients treated with the OXA–GE
combination have been reported to experience response rates
Table 5 Published studies with gemcitabine and oxaliplatin in cancer patients
Reference Ph
No. of
patients Disease
Schedule
(mgm
 2)
Lines
of CT % OR MTD DLT
Grade 3–4
haematotox
Grade 2–3
non-haematotox
All tumours
Mavroudis et al (2000) I 48 All O: 120 D1
G: 100–1600 D1, D8
Every 3w
35% 1L
23% 2L
42%X3L
13 G:1600
O:120
9% PNN
5% PLT
1% Hb
29% asthaenia
9% vomiting
7% oedema
4% diarrhoea
No DLT 6% neuroT
Gandara et al (2001) I 21 All O: 130 D1
G: 1250 D1D8
Every 3w
100% p4 0 G: 1000
O: 130
DLT: PLT
and confusion
ND ND
Faivre et al (2002) I/II 44 35 pulm
9O v
O: 70–100 D1
G: 800–1600 D1
Every 2w
69% 1L
20% 2L
11% 3L
P3 3
Ov 33
G: 1500
O: 85
No DLT
20% PNN
9% PLT
45% asthaenia
39% vomiting
43% neuroT
Franciosi et al (2003) II 32 Pulm O: 85 D1, D8
G: 1000 D1, D8
Every 3w
75% 1 L
25% 2L
16 13% PNN
23% PLT
3% vomiting
9% hepatic
6% diarrhoea
9% neuroT
Pectasides et al (2004) II 26 Germ cell O: 130 D1
G: 1000 D1, D8
Every 3w
62% 2L
38% 3L
32 62% PNN
41% PLT
27% vomiting
17% asthaenia
3% diarrhoea
10% neuroT
Theodore et al (2006) II 30 TCC O: 85 D1
G: 1500 D1
Every 2w
100% 1L 47 10% PNN
2% PLT
80% Asthaenia
24% Vomiting
39% neuroT
Louvet et al (2002) II 64 Pancreas O: 100 D2
G: 1000 D1
Every 2w
100% 1L 30 11% PNN
11% PLT
14% asthaenia
14% vomiting
11% neuroT
Ovarian T only
Raspagliesi et al (2004) II 20 Ov O: 130 D8
G: 1000 D1D8
Every 3w
100% 2L 26 40% PNN
70% PLT
15% Hb
45% vomiting
20% neuroT
15% hepatic
10% allergic
Steer et al (2006) II 20 Ov O: 130 D8
G: 1250 D1D8
Every 3w
100% 1L 80 25% PNN
5% Hb
15% asthaenia
5% hepatic
5% diarrhoea
10% vomiting
20% neuroT
Germano et al (2007) II 21 Ov O:100 D2
G: 1000 D1
Every 2w
50% 2L
50% 3L
23 30% PLT Grade I-II:
38% nausea
38% neuroT
Harnett et al (2007) II 75 Ov O: 130 D8
G: 1000 D1D8
Every 3w
100% 2L 20 61% PNN
10% PLT
16% nausea
22% vomiting
9% neuroT
7% dyspnoea
Present study II 50 Ov O:100 D1
G: 1000 D1D8
Every 3w
84% 2L
16% 3L
37 51% PNN
26% PLT
12% Hb
32% nausea
41% asthaenia
3% diarrhoea
3% allergic
7% neuroT
Abbreviations: CT¼chemotherapy; D¼day; DLT¼dose-limiting toxicity; G¼gemcitabine; hemato tox¼haematological toxicity; L¼line; MDT¼maximal dose tolerated;
neuroT¼neurotoxicity; O¼oxaliplatin; OR¼objective response; Ov¼ovarian cancer; P¼pulmonary; Ph¼phase; PLT¼platelet; PLT¼platelet; PNN¼polynuclear
neutrophil; TCC¼transitional cell carcinoma; w¼weeks.
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with median PFS and OS of 5.0 and 9.2 months, respectively.
(Raspagliesi et al, 2004; Harnett et al, 2007). The results reported
in the present study fall in the same range as those of earlier
reports.
The last, but not least, question to be discussed is the benefit of
the combination over single-agent therapy for this subset of very
poor prognosis patients. Our non-randomised study cannot
provide a clear-cut answer to this fundamental question. Several
studies in resistant ovarian cancer patients have failed to find a
median PFS or OS advantage of combinations of doxorubicin or
epirubicin with paclitaxel over paclitaxel alone, or of doublets
including topotecan over topotecan alone, suggesting that non-
platinum single-agent therapy might be the most appropriate
treatment in this setting (Bolis et al, 1999; Buda et al, 2004; Sehouli
et al, 2008). The median time to progression of 4.6 months and the
median OS of 11.4 months in resistant or refractory patients
treated with OXA and GE in our study also appear comparable to
survival durations reported in earlier trials of liposomal pegylated
doxorubicin, topotecan or weekly paclitaxel used as single agents
(Gordon et al, 2001; Markman et al, 2006). However, median PFS
and OS, in contrast to disease control and quality of life, may not
be the most relevant end-points for trials conducted in patients
with refractory or resistant ovarian cancer. If we consider the
entire study population, the GE–OXA combination induced
response or stable disease in 63% of the cases, allowing prolonged
disease control with acceptable side effects in a majority of
patients. The high response rate reported with the GE–OXA
regimen in our patients as well as in other studies might be of
value in a selected population of treatment-resistant patients who
complain of symptoms and need rapid relief. This should be
confirmed in more adapted trials in which long-term improvement
of symptoms could be a relevant end-point to compare the benefits
of combination with those of single-agent therapy. The GE–OXA
combination has shown significant response rates, both in the nine
patients with TFI between 0 and 3 months (44% overall response
rate) and in the 33 patients who relapsed between 3 and 6 months
after treatement (42% response rate), thus encouraging its use in
patients with symptomatic disease. This high activity of OXA–GE
should, however, be balanced against the increased toxicity of the
combination compared with single-drug regimens. A comparison
of the duration of disease control and patient quality of life
achieved with OXA–GE or non-platinum agents used as single
agents is warranted.
Finally, our multicentre experience of the OXA–GE combina-
tion in patients with resistant ovarian cancer is close to that
reported in other types of platinum-refractory tumours (Faivre
et al, 2002; Franciosi et al, 2003; Pectasides et al, 2004). Despite
experimental (Bergman et al, 1996) and clinical evidence of
synergism between these two drugs, their optimal administration,
either sequential or concurrent, remains to be determined in
resistant ovarian cancer patients.
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